A cohort study of the ocular safety of anti-ulcer drugs.
1. Recently, some cases have been reported where intravenous use of omeprazole was followed by loss of vision. We followed up a cohort of close to 140,000 persons during periods of treatment and non-treatment with five anti-ulcer drugs. 2. The relative risk of vascular disorders of the eye during use of omeprazole compared with non-use was 1.8 (95% CI 0.5-6.0). Use of other anti-ulcer drugs was associated with a similar risk of vascular disorders. The relative risk associated with current use of any anti-ulcer drug was 1.9 (95% CI 1.1-3.4). We did not find a single case of optic inflammatory disorder during treatment with any of the five anti-ulcer drugs. 3. These results do not suggest a major increased risk for vascular or inflammatory disorders of the eye associated with use of omeprazole or other anti-ulcer drugs.
García Rodríguez
L A
LA
Centro Español de Investigación Farmacoepidemiológica, Universidad Complutense de Madrid, Spain.
Mannino
S
S
Wallander
M A
MA
Lindblom
B
B
D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D005128:Eye Diseases / Q000209:etiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects; D012189:Retrospective Studies; D014456:Ulcer / Q000188:drug therapy; D006113:United Kingdom
D000897:Anti-Ulcer Agents; D009853:Omeprazole